Gapping up
In reaction to earnings/guidance:
- EXTR +18.2% (raises Q1 EPS and revenue guidance above consensus)
- GNMK +13.3% (guides Q3 revs above consensus; also announces it has received EUA from the FDA for ePlex)
- MATX +7.8% (issues upside Q3 EPS guidance)
- HCA +6.2% (guides Q3 revs above consensus; will return or repay early $6 bln of govt assistance from CARES Act)
- NXPI +5.1% (raises Q3 rev guidance above consensus)
M&A news:
- XLNX +16.4% (on reports that AMD is in advanced talks to buy rival chip maker Xilinx)
- MXIM +1.5% / ADI +1% (shareholders vote to approve ADI/MXIM merger; also in sympathy with strong NXPI guidance)
Select metals/mining stocks trading higher:
- HMY +3.7%, GFI +3.4%, AU +3.4%, GDX +2.2%, KGC +1.9%, GOLD +1.7%, FCX +1.7%, AUY +1.5%, NEM +1.4%, NG +1.4%, GLD +1.2%
Select cannabis related names showing strength:
- TLRY +9.8%, ACB +8.4%, MJ +4.2%, APHA +3.2%, CGC +2.8%
Other news:
- MVIS +29% (attributed to positive blog mention)
- PGEN +8.8% (Precigen announces Merck KGaA increases ownership position through exercise of convertible note)
- SELB +9.3% (enters into a research agreement with IGAN Biosciences)
- AXGT +4.9% (received Rare Pediatric Disease Designation from the FDA for AXO-AAV-GM1 )
- HL +3.8% (reports Q3 production; reaffirms increased annual silver and gold production guidance)
- VLDR +2.7% (the co and and RoboSense announced that the two companies have entered a long-term global cross-licensing relationship encompassing a broad range of 360 surround-view lidar sensors)
- VERI +2.4% (new CFO)
- GILD +2.1% (final results of NIAID ACTT-1 trial published in NEJM)
- MCHP +1.6% / SWKS +0.5% (in sympathy with strong NXPI guidance)
- CCL +1.4% (CEO on CNBC: Says a vaccine would be helpful, but just one tool in the toolbox)
- ET +1.4% (names new co-CEOs)
- EXEL +0.8% (disclosed new preclinical data showing that AUR102 has potent anti-tumor activity in a large panel of cancer cell lines)
- GRFS +0.6% (Grifols, S.A.'s anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19)
- AMZN +0.5% (confirms Prime Pay will start October 13 in 19 countries worldwide)
- AAPL +0.3% (to extend Apple TV+ free trials for three months, according to CNBC; iPhone 12 details have been leaked ahead of event on Tuesday)
Analyst comments:
- RKT +6.2% (upgraded to Overweight from Neutral at JPMorgan)
- LILA +5.6% (upgraded to Overweight at Morgan Stanley)
- GE +4.2% (reinstated with Buy at Goldman)
- W +2.2% (upgraded to Outperform from Market Perform at William Blair)
- BIG +1.5% (initiated with an Outperform at Wolfe Research; tgt $61)
- IP +1.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- RNG +1.4% (initiated with a Buy at Mizuho)
- ZM +1.1% (initiated with a Buy at Mizuho)
- ROKU +1.1% ( target raised to $255 at Needham on installed base acceleration)
- DAR +0.9% (initiated with a Buy at Tudor Pickering)
- MDT +0.6% (upgraded to Outperform from Market Perform at Bernstein)